<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759209</url>
  </required_header>
  <id_info>
    <org_study_id>VirtualBx/KT</org_study_id>
    <nct_id>NCT04759209</nct_id>
  </id_info>
  <brief_title>Development and Validation of a Virtual Biopsy System in Kidney Transplant</brief_title>
  <official_title>Development and Validation of a Machine Learning Based Virtual Biopsy System in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paris Translational Research Center for Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - HÃ´pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Hospital Centre Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Paris Translational Research Center for Organ Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, kidney allograft biopsies are routinely performed to determine diagnosis and&#xD;
      prognosis of kidney allografts. The histological interpretation of these biopsies is based on&#xD;
      the Banff consensus for renal allograft pathology. The purpose of this study is to provide to&#xD;
      the physicians a reliable estimation of renal allograft lesions of the day zero biopsy&#xD;
      (kidney donor biopsy performed before transplantation).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In kidney transplantation, day-zero biopsies are essential to assess organ quality and&#xD;
      discriminate the donor transmitted or acquired lesions and disease progression&#xD;
      post-transplant. However, many centers worldwide do not perform those biopsies because they&#xD;
      are invasive and costly. We aimed to develop and validate a non-invasive virtual biopsy&#xD;
      system. Our goal was to provide clinicians with a virtual biopsy system to guide diagnostics,&#xD;
      therapeutics and immediate patient management post-transplant and to minimize additional&#xD;
      risks and costs to perform day-zero biopsies only using standard donor parameters. To&#xD;
      circumvent these limitations, we sought to build and validate a virtual biopsy system that&#xD;
      uses routinely collected donor parameters to predict kidney day-zero biopsy results. Since&#xD;
      machine learning has demonstrated its clinical relevance in many medical specialties and&#xD;
      superior performance to logistic regression, we based our analyses on machine learning&#xD;
      methods as well as traditional statistical approaches using large and qualified international&#xD;
      cohort donors who underwent routine and protocolized collection of donor parameters together&#xD;
      with day-zero biopsy assessment using the standards of the international Banff allograft&#xD;
      histopathology classification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2000</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arteriosclerosis score according to Banff International Classification</measure>
    <time_frame>up to 1 day post-transplant</time_frame>
    <description>Arteriosclerosis defined by arterial intimal thickening in the most severely affected artery (Banff &quot;cv&quot; score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arteriolar Hyalinosis score according to Banff International Classification</measure>
    <time_frame>up to 1 day post-transplant</time_frame>
    <description>arteriolar hyalinosis defined by periodic acid-Schiff (PAS)-positive arteriolar hyaline thickening (Banff &quot;ah&quot; score),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interstitial fibrosis and tubular atrophy score according to Banff International Classification</measure>
    <time_frame>up to 1 day post-transplant</time_frame>
    <description>interstitial fibrosis and tubular atrophy computed with the extent of cortical fibrosis (Banff &quot;ci&quot; score) and cortical tubular atrophy (Banff &quot;ct&quot; score).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Continuous percentage of sclerotic glomeruli</measure>
    <time_frame>up to 1 day post-transplant</time_frame>
    <description>continuous percentage of sclerotic glomeruli is defined by the percentage of the total number of glomeruli affected by global sclerosis</description>
  </primary_outcome>
  <enrollment type="Actual">12992</enrollment>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biopsies</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Living or deceased kidney donors who underwent a kidney biopsy performed prior to kidney&#xD;
        transplantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Kidney donors who underwent kidney biopsies performed prior to kidney transplantation,&#xD;
        aged at least 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inadequate biopsies according to Banff international classification (number of&#xD;
             glomeruli less than 10),&#xD;
&#xD;
          -  biopsies with two or more Banff scores of interest missing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Loupy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Translational Research Center for Organ Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paris Transplant Group</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Day-zero biopsy</keyword>
  <keyword>Machine learning</keyword>
  <keyword>Non-invasive biopsy</keyword>
  <keyword>Common parameters</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

